George Silva

NPI: 1922000769
Total Payments
$2,961
2024 Payments
$1,197
Companies
21
Transactions
106
Medicare Patients
15
Medicare Billing
$920.12

Payment Breakdown by Category

Food & Beverage$1,853 (62.6%)
Research$1,108 (37.4%)

Payments by Nature

Nature of Payment Amount Transactions Share
Food and Beverage $1,853 98 62.6%
Unspecified $1,108 8 37.4%

Payments by Type

General
$1,853
98 transactions
Research
$1,108
8 transactions

Top Paying Companies

Company Total Records Latest Year
ABBVIE INC. $1,345 19 $0 (2024)
Abbott Laboratories $366.97 18 $0 (2024)
Novo Nordisk Inc $246.45 15 $0 (2020)
Salix Pharmaceuticals, a division of Bausch Health US, LLC $145.17 1 $0 (2023)
Merck Sharp & Dohme Corporation $142.28 9 $0 (2020)
Lilly USA, LLC $104.66 7 $0 (2019)
AstraZeneca Pharmaceuticals LP $100.16 5 $0 (2020)
Janssen Pharmaceuticals, Inc $82.24 5 $0 (2018)
Takeda Pharmaceuticals America, Inc. $58.62 4 $0 (2017)
Takeda Pharmaceuticals U.S.A., Inc. $55.66 5 $0 (2018)

Payment History by Year

Year Amount Transactions Top Company
2024 $1,197 13 ABBVIE INC. ($1,108)
2023 $286.89 8 Salix Pharmaceuticals, a division of Bausch Health US, LLC ($145.17)
2022 $129.64 6 Abbott Laboratories ($92.28)
2021 $90.83 4 AbbVie Inc. ($46.97)
2020 $151.78 8 Genentech USA, Inc. ($24.48)
2019 $442.58 26 Novo Nordisk Inc ($116.61)
2018 $350.13 22 AbbVie, Inc. ($106.30)
2017 $312.51 19 Janssen Pharmaceuticals, Inc ($65.37)

All Payment Transactions

106 individual payment records from CMS Open Payments — Page 1 of 5

Date Company Product Nature Form Amount Type
11/15/2024 ABBVIE INC. In-kind items and services $375.96 Research
Study: A Phase 2a Multicenter, Randomized, Platform Study of Targeted Therapies for the Treatment of Adult Subjects With Moderate to Severe Crohn's Disease
11/15/2024 ABBVIE INC. In-kind items and services $50.00 Research
Study: A Phase 2a Multicenter, Randomized, Platform Study of Targeted Therapies for the Treatment of Adult Subjects With Moderate to Severe Crohn's Disease
11/15/2024 ABBVIE INC. In-kind items and services $50.00 Research
Study: A Phase 2a Multicenter, Randomized, Platform Study of Targeted Therapies for the Treatment of Adult Subjects With Moderate to Severe Crohn's Disease
11/15/2024 ABBVIE INC. In-kind items and services $24.99 Research
Study: A Phase 2a Multicenter, Randomized, Platform Study of Targeted Therapies for the Treatment of Adult Subjects With Moderate to Severe Crohn's Disease
11/15/2024 ABBVIE INC. In-kind items and services $22.63 Research
Study: A Phase 2a Multicenter, Randomized, Platform Study of Targeted Therapies for the Treatment of Adult Subjects With Moderate to Severe Crohn's Disease
11/15/2024 Abbott Laboratories FREESTYLE LIBRE 3 (Device) Food and Beverage In-kind items and services $19.56 General
Category: Diabetes Care
11/14/2024 ABBVIE INC. In-kind items and services $220.71 Research
Study: A Phase 2a Multicenter, Randomized, Platform Study of Targeted Therapies for the Treatment of Adult Subjects With Moderate to Severe Crohn's Disease
11/14/2024 ABBVIE INC. In-kind items and services $142.90 Research
Study: A Phase 2a Multicenter, Randomized, Platform Study of Targeted Therapies for the Treatment of Adult Subjects With Moderate to Severe Crohn's Disease
11/13/2024 ABBVIE INC. In-kind items and services $220.71 Research
Study: A Phase 2a Multicenter, Randomized, Platform Study of Targeted Therapies for the Treatment of Adult Subjects With Moderate to Severe Crohn's Disease
09/13/2024 Abbott Laboratories FREESTYLE LIBRE 3 (Device) Food and Beverage In-kind items and services $18.98 General
Category: Diabetes Care
06/04/2024 Abbott Laboratories FREESTYLE LIBRE 3 (Device) Food and Beverage In-kind items and services $15.10 General
Category: Diabetes Care
05/02/2024 Abbott Laboratories FREESTYLE LIBRE 3 (Device) Food and Beverage In-kind items and services $17.53 General
Category: Diabetes Care
03/06/2024 Abbott Laboratories FREESTYLE LIBRE 3 (Device) Food and Beverage In-kind items and services $17.94 General
Category: Diabetes Care
12/24/2023 Abbott Laboratories FREESTYLE LIBRE 3 (Device) Food and Beverage In-kind items and services $12.70 General
Category: Diabetes Care
12/14/2023 Salix Pharmaceuticals, a division of Bausch Health US, LLC XIFAXAN (Drug) Food and Beverage In-kind items and services $145.17 General
Category: Gastroenterology
09/19/2023 Abbott Laboratories FREESTYLE LIBRE 2 (Device) Food and Beverage In-kind items and services $24.34 General
Category: Diabetes Care
08/03/2023 Abbott Laboratories FREESTYLE LIBRE 2 (Device) Food and Beverage In-kind items and services $24.09 General
Category: Diabetes Care
08/03/2023 Abbott Laboratories FREESTYLE LIBRE 2 (Device) Food and Beverage In-kind items and services $22.29 General
Category: Diabetes Care
06/04/2023 Abbott Laboratories FREESTYLE LIBRE 2 (Device) Food and Beverage In-kind items and services $21.08 General
Category: Diabetes Care
04/27/2023 Abbott Laboratories FREESTYLE LIBRE 2 (Device) Food and Beverage In-kind items and services $23.82 General
Category: Diabetes Care
01/06/2023 Abbott Laboratories FREESTYLE LIBRE 2 (Device) Food and Beverage In-kind items and services $13.40 General
Category: Diabetes Care
10/04/2022 Abbott Laboratories FREESTYLE LIBRE 2 (Device) Food and Beverage In-kind items and services $23.38 General
Category: Diabetes Care
08/24/2022 Abbott Laboratories FREESTYLE LIBRE 2 (Device) Food and Beverage In-kind items and services $24.30 General
Category: Diabetes Care
07/15/2022 Abbott Laboratories FREESTYLE LIBRE 2 (Device) Food and Beverage In-kind items and services $22.98 General
Category: Diabetes Care
06/08/2022 ABBVIE INC. UBRELVY (Drug) Food and Beverage In-kind items and services $23.03 General
Category: NEUROSCIENCE

Research Studies & Clinical Trials

Study Name Company Amount Records
A Phase 2a Multicenter, Randomized, Platform Study of Targeted Therapies for the Treatment of Adult Subjects With Moderate to Severe Crohn's Disease ABBVIE INC. $1,108 8

Medicare Billing by Year

Year Procedures Beneficiaries Services Submitted Medicare Paid
2020 1 15 16 $3,200 $920.12
Total Patients
15
Total Services
16
Medicare Billing
$920.12
Procedure Codes
1

All Medicare Procedures & Services

1 procedure records from CMS Medicare Utilization

HCPCS Description Setting Year Patients Services Charges Medicare Paid Ratio
99213 Established patient office or other outpatient visit, typically 15 minutes Office 2020 15 16 $3,200 $920.12 28.8%

About George Silva

George Silva is a Family Medicine healthcare provider based in Mashpee, Massachusetts. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/11/2005. The National Provider Identifier (NPI) number assigned to this provider is 1922000769.

According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, George Silva has received a total of $2,961 in payments from pharmaceutical and medical device companies, with $1,197 received in 2024. These payments were reported across 106 transactions from 21 companies. The most common payment nature is "Food and Beverage" ($1,853).

As a Medicare-enrolled provider, Silva has provided services to 15 Medicare beneficiaries, totaling 16 services with total Medicare billing of $920.12. Data is available for 1 year (2020–2020), covering 1 distinct procedure/service records.

Practice Information

  • Specialty Family Medicine
  • Location Mashpee, MA
  • Active Since 08/11/2005
  • Last Updated 10/04/2010
  • Taxonomy Code 207Q00000X
  • Entity Type Individual
  • Practice Solo Practitioner
  • NPI Number 1922000769

Products in Payments

  • FREESTYLE LIBRE 2 (Device) $221.30
  • XIFAXAN (Drug) $145.17
  • Synthroid (Drug) $129.74
  • FREESTYLE LIBRE 3 (Device) $101.81
  • Trintellix (Drug) $94.14
  • JANUVIA (Drug) $88.98
  • Ozempic (Drug) $69.84
  • INVOKANA (Drug) $65.37
  • Saxenda (Drug) $64.55
  • FARXIGA (Drug) $62.84
  • TRULICITY (Drug) $60.28
  • UBRELVY (Drug) $59.94
  • VRAYLAR (Drug) $47.56
  • FreeStyle Libre 2 (Device) $43.86
  • Xofluza (Drug) $43.42
  • Livalo (Drug) $40.65
  • SYMBICORT (Drug) $37.32
  • Prolia (Biological) $35.38
  • EMGALITY (Drug) $30.60
  • VYVANSE (Drug) $30.40

Data Sources

Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.

Family Medicine Doctors in Mashpee